C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.455
-0.085 (-3.35%)
Oct 21, 2025, 3:56 PM EDT - Market open
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $6.46M in the quarter ending June 30, 2025, a decrease of -46.17%. This brings the company's revenue in the last twelve months to $34.24M, up 16.55% year-over-year. In the year 2024, C4 Therapeutics had annual revenue of $35.58M with 71.44% growth.
Revenue (ttm)
$34.24M
Revenue Growth
+16.55%
P/S Ratio
5.23
Revenue / Employee
$311,273
Employees
110
Market Cap
174.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 35.58M | 14.83M | 71.44% |
Dec 31, 2023 | 20.76M | -10.34M | -33.25% |
Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CCCC News
- 5 days ago - C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - GlobeNewsWire
- 20 days ago - C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics, Inc. - Special Call - Seeking Alpha
- 4 weeks ago - C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting - GlobeNewsWire
- 6 weeks ago - C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewsWire
- 6 weeks ago - C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 2 months ago - C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - C4 Therapeutics: An Entry Point If There's Ever Going To Be One - Seeking Alpha